Filing Flows › Comparisons › VERA vs ZBIO
Vera Therapeutics vs Zenas BioPharma: VERA and ZBIO compared
Vera Therapeutics is the larger company: $10.3M of revenue in its latest quarter (Q3 2026) against $10.0M for Zenas BioPharma (Q3 2026).
Where the money goes: VERA and ZBIO
Vera Therapeutics (VERA) · Q3 2026
Vera Therapeutics, Q3 2026: revenue $10.3M, operating margin -931.2%, net loss $93.7M, operating cash flow −$99.2M. The chart follows the revenue to costs, profit and cash.
Zenas BioPharma (ZBIO) · Q3 2026
Zenas BioPharma, Q3 2026: revenue $10.0M, net loss $109M, operating cash flow −$58.0M. The chart follows the revenue to costs, profit and cash.
| Vera Therapeutics (VERA) | Zenas BioPharma (ZBIO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $10.3M | $10.0M |
| Operating margin | -931.2% | n/m |
| Net earnings | −$93.7M | −$109M |
| Net margin | -911.9% | — |
| Operating cash flow | −$99.2M | −$58.0M |
Questions
Which is bigger, Vera Therapeutics or Zenas BioPharma?
Vera Therapeutics is the larger company: $10.3M of revenue in its latest quarter (Q3 2026) against $10.0M for Zenas BioPharma (Q3 2026).
More: Vera Therapeutics earnings · how Vera Therapeutics makes money · Zenas BioPharma earnings · how Zenas BioPharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.